Trellus Health PLC (LSE:TRLS) has secured a $600,000 unsecured loan from major shareholder Icahn School of Medicine at Mount Sinai, providing additional liquidity to support its commercial initiatives and extending its cash runway through January 2026. The facility carries no interest for the first six months and is intended to help the company deepen its engagement with pharmaceutical partners and contract research organizations. Trellus has recently signed agreements with two global CROs, with clinical trial implementations targeted before the end of the year.
More about Trellus Health PLC
Trellus Health PLC is a healthcare innovator delivering value-based solutions for individuals managing chronic conditions. Its flagship platform, Trellus Elevate®, integrates data analytics with personalized resilience-building programs, initially focused on gastrointestinal diseases such as IBD. The company also offers Trellus TrialSet™, a tool designed to enhance clinical trial support and patient engagement for pharmaceutical collaborators.
Leave a Reply